Definium Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -44.7% | -44.7% | -41.6% |
| FY2021 | -61.3% | -61.3% | -56.7% |
| FY2022 | -37.6% | -37.6% | -33.4% |
| FY2023 | -122.5% | -103.8% | -76.9% |
| FY2024 | -45.0% | -41.3% | -36.0% |
| FY2025 | -55.3% | -49.3% | -41.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -44.7% | -44.7% | -41.6% |
| FY2021 | -61.3% | -61.3% | -56.7% |
| FY2022 | -37.6% | -37.6% | -33.4% |
| FY2023 | -122.5% | -103.8% | -76.9% |
| FY2024 | -45.0% | -41.3% | -36.0% |
| FY2025 | -55.3% | -49.3% | -41.8% |